Analyst Price Targets — RXST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 10:53 am | — | Stifel Nicolaus | $7.00 | $6.26 | TheFly | RxSight price target lowered to $7 from $8 at Stifel |
| July 28, 2026 12:03 pm | — | UBS | $5.50 | $5.94 | TheFly | RxSight resumed with a Neutral at UBS |
| July 7, 2026 7:37 pm | — | Jefferies | $6.50 | $5.62 | TheFly | RxSight price target lowered to $6.50 from $7.50 at Jefferies |
| May 7, 2026 12:00 pm | — | Needham | $11.00 | $6.03 | TheFly | RxSight price target lowered to $11 from $13 at Needham |
| March 9, 2026 11:12 am | Thomas Stephan | Stifel Nicolaus | $9.00 | $7.57 | TheFly | RxSight price target lowered to $9 from $10 at Stifel |
| February 26, 2026 11:09 am | David Saxon | Needham | $13.00 | $8.81 | StreetInsider | Needham Reiterates Buy Rating on RxSight Inc. (RXST) |
| January 20, 2026 11:45 am | — | Piper Sandler | $11.00 | $9.81 | TheFly | RxSight price target raised to $11 from $10 at Piper Sandler |
| December 2, 2025 11:39 am | — | Morgan Stanley | $10.00 | $11.65 | TheFly | RxSight price target raised to $10 from $9 at Morgan Stanley |
| November 6, 2025 4:57 pm | — | Stifel Nicolaus | $10.00 | $8.73 | TheFly | RxSight price target raised to $10 from $8 at Stifel |
| October 29, 2024 8:11 am | Curry Baker | Guggenheim | $52.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
Latest News for RXST
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
RxSight (NASDAQ: RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business. Excluding the Alcon-related revenue, product sales were $27.2 million, down 19% from the prior-year period.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RXST.
U.S. House Trading
No House trades found for RXST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.